PTAB Axes OxyContin Patent After Purdue Ch. 11 Delay



By Andrew Karpan (Nov 22, 2021, 9:07 p.m. EST) – The Patent Trial and Appeal Board has invalidated a Purdue Pharma patent for an opioid with an anti-abuse deterrent, attacking the patent description and dismissing Purdue’s argument that the Commission took too long to make a decision.

Friday’s Patent Board decision came more than two years after a decision on Collegium Pharmaceutical’s post-grant petition was initially due. The delay was caused by Purdue’s September 2019 bankruptcy filing in an attempt to stem the wave of lawsuits the company has faced for its role in marketing drugs in the opioid crisis.

The filing of chapter 11 put a stopper …

Stay one step ahead

In the legal profession, information is the key to success. You need to know what’s going on with customers, competitors, practice areas, and industries. Law360 provides the intelligence you need to stay an expert and beat the competition.

  • Access to case data in articles (numbers, filings, courts, nature of prosecution, etc.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, requests, etc.
  • Create personalized alerts for specific case articles and topics and more!

TRY LAW360 FREE FOR SEVEN DAYS


Previous SmilePath Announces 4-Month At-Home Tooth Smoothing Product
Next How to consolidate debt with a high debt-to-income ratio - Forbes Advisor